Skip to main content

Table 4 Predictive performance of the number of positive markers among the 19 markers

From: A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA

Marker

Sample type

#Pos/#Cases

Sensitivity (95% CI)

#Neg/#Controls

Specificity (95% CI)

PPV (95% CI)

NPV (95% CI)

≥ 1 of 19

DRE

38/38

1.00 (1.00, 1.00)

7/49

0.14 (0.06, 0.24)

0.47 (0.45, 0.51)

1.00 (1.00, 1.00)

FV

32/32

1.00 (1.00, 1.00)

4/35

0.11 (0.03, 0.23)

0.51 (0.48, 0.54)

1.00 (1.00, 1.00)

≥ 2 of 19

DRE

38/38

1.00 (1.00, 1.00)

15/49

0.31 (0.18, 0.43)

0.53 (0.49, 0.58)

1.00 (1.00, 1.00)

FV

32/32

1.00 (1.00, 1.00)

8/35

0.23 (0.11, 0.37)

0.54 (0.51, 0.59)

1.00 (1.00, 1.00)

≥ 3 of 19

DRE

37/38

0.97 (0.92, 1.00)

18/49

0.37 (0.24, 0.51)

0.54 (0.49, 0.60)

0.95 (0.83, 1.00)

FV

32/32

1.00 (1.00, 1.00)

13/35

0.37 (0.23, 0.54)

0.59 (0.54, 0.67)

1.00 (1.00, 1.00)

≥ 4 of 19

DRE

36/38

0.95 (0.87, 1.00)

25/49

0.51 (0.38, 0.65)

0.60 (0.54, 0.68)

0.93 (0.82, 1.00)

FV

31/32

0.97 (0.91, 1.00)

19/35

0.54 (0.37, 0.71)

0.66 (0.58, 0.74)

0.95 (0.85, 1.00)

≥ 5 of 19

DRE

36/38

0.95 (0.87, 1.00)

30/49

0.61 (0.47, 0.76)

0.65 (0.58, 0.74)

0.94 (0.85, 1.00)

FV

31/32

0.97 (0.91, 1.00)

23/35

0.66 (0.51, 0.80)

0.72 (0.64, 0.82)

0.96 (0.88, 1.00)

≥ 6 of 19

DRE

34/38

0.89 (0.79, 0.97)

35/49

0.71 (0.59, 0.86)

0.71 (0.62, 0.82)

0.90 (0.81, 0.97)

FV

30/32

0.94 (0.84, 1.00)

25/35

0.71 (0.57, 0.86)

0.75 (0.66, 0.86)

0.93 (0.83, 1.00)

≥ 7 of 19

DRE

32/38

0.84 (0.74, 0.95)

38/49

0.78 (0.65, 0.90)

0.74 (0.65, 0.87)

0.86 (0.78, 0.95)

FV

26/32

0.81 (0.69, 0.94)

27/35

0.77 (0.63, 0.91)

0.76 (0.66, 0.89)

0.82 (0.71, 0.93)

≥ 8 of 19

DRE

30/38

0.79 (0.66, 0.92)

43/49

0.88 (0.78, 0.96)

0.83 (0.73, 0.94)

0.84 (0.76, 0.93)

FV

21/32

0.66 (0.50, 0.81)

30/35

0.86 (0.74, 0.97)

0.81 (0.68, 0.95)

0.73 (0.64, 0.84)

≥ 9 of 19

DRE

28/38

0.74 (0.61, 0.87)

44/49

0.90 (0.82, 0.98)

0.85 (0.74, 0.97)

0.81 (0.74, 0.90)

FV

19/32

0.59 (0.44, 0.75)

32/35

0.91 (0.83, 1.00)

0.86 (0.74, 1.00)

0.71 (0.63, 0.81)

≥ 10 of 19

DRE

27/38

0.71 (0.58, 0.84)

46/49

0.94 (0.86, 1.00)

0.90 (0.80, 1.00)

0.81 (0.74, 0.89)

FV

16/32

0.50 (0.34, 0.66)

33/35

0.94 (0.86, 1.00)

0.89 (0.75, 1.00)

0.67 (0.61, 0.76)

≥ 11 of 19

DRE

22/38

0.58 (0.43, 0.74)

47/49

0.96 (0.90, 1.00)

0.92 (0.81, 1.00)

0.75 (0.69, 0.83)

FV

12/32

0.38 (0.22, 0.53)

33/35

0.94 (0.86, 1.00)

0.86 (0.69, 1.00)

0.62 (0.57, 0.69)

≥ 12 of 19

DRE

13/38

0.34 (0.21, 0.50)

49/49

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

0.66 (0.62, 0.72)

FV

9/32

0.28 (0.16, 0.44)

33/35

0.94 (0.86, 1.00)

0.82 (0.62, 1.00)

0.59 (0.54, 0.65)

≥ 13 of 19

DRE

11/38

0.29 (0.17, 0.45)

49/49

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

0.64 (0.61, 0.70)

FV

7/32

0.22 (0.09, 0.38)

35/35

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

0.58 (0.55, 0.64)

≥ 14 of 19

DRE

9/38

0.24 (0.13, 0.37)

49/49

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

0.63 (0.60, 0.67)

FV

5/32

0.16 (0.06, 0.28)

35/35

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

0.56 (0.54, 0.60)

≥ 15 of 19

DRE

7/38

0.18 (0.08, 0.32)

49/49

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

0.61 (0.58, 0.65)

FV

3/32

0.09 (0.03, 0.22)

35/35

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

0.55 (0.53, 0.58)

  1. The calculated sensitivity and specificity, positive predictive value (PPV), and negative predictive value (NPV) associated with n of 19 positive markers for DRE and FV urine samples. The column #Pos/#Cases shows the number of positive cases and the total number of cases. The column #Neg/#Controls shows the number of negative controls and the total number of controls. The numbers in the parentheses show the 95% confidence interval
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us